Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.59 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21925053 | 0.78 | FDPS (0.60) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL7785400 | 0.78 | GGPS1 (0.53) | FDPSGGPS1SMPD1LPAR1LPAR3 | |
| SCHEMBL751282 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL9635795 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL16472626 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL23403758 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL5279240 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL8685348 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL5051060 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 | |
| SCHEMBL8687314 | 0.77 | FDPS (0.52) | FDPSGGPS1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293214-B2 | Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds | BRACCO SUISSE S.A. (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20100008863-A1 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COMPOUNDS | BRACCO SUISSE SA (CH) | 2010-01-14 | — | — | US | disclosed |
| EP-2117603-A2 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COMPOUNDS | BRACCO INTERNATIONAL B.V. (NL) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008075192-A2 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COM OUNDS | BRACCO INTERNATIONAL BV (NL) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008863-A1 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COMPOUNDS | SGMS1, SGMS2, MSR1 | FDPS 280/4885GGPS1 265/4885SMPD1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.